Daily Top 50 Gainers & Losers

Market Regime — the colored bar under each day is the market's overall “weather,” scored from the indexes (trend, fear/VIX, small-cap breadth). It's market-wide context, not a stock pick: even a great company gets dragged down in a red tape. Read it to gauge when to lean in vs. wait for calmer water — click any day for the full read.

Risk-On · supportive Neutral Risk-Off · headwind Stress · fear

Market Recap · Wednesday, August 12, 2026

Snapshot: Aug 12, 2026 · 6:00 PM 100 stocks analyzed

Up Day

Wed, Aug 12, 2026 Broad Rally High

Broad rally with extreme single-stock dispersion as tech gainers soared 32% of top movers; Russell 2000 led with 0.87%, small caps outpacing the S&P, while healthcare dominated …

55% S&P 500 rose 0.32% in a broad_rally regime with all indices positive, Russell 2000 outpacing at 0.87% and mid-caps at 1.34%, signaling small-cap leadership as VIX fell nearly 4% on the up day—a calm-confidence tape.
30% Extreme dispersion lit up the edges with 50 gainers averaging +29% (IVDA +82%, GXAI +60%, MYSEW +60%) against 50 losers averaging -24%, anchored by news-grounded beats (Nebius AI +21%, Quantinuum +27%, Omer +24%) and biotech rebounds (SION +29% after 90% prior crash).
15% Healthcare dominated losers at 31% of decliners while Technology claimed 32% of gainers, creating stark sector dispersion; five debutants entered gainers list (CHOW, TCGX, FEED, SMWB, GRWG), and SLXN extended a 3-day losing streak on dilutive equity offering.

Technology drove 32% of gainers 5 names returned after long absences SLXN · 3-day losers streak CHOW — first appearance TCGX — first appearance

Market Regime

Wed, Aug 12, 2026 Risk-On conf: medium macro · prototype

+51

Tailwind −100 … +100 · + tailwind / − headwind

VIX14.6 p1 Drawdown-0.1% Held8d · established SinceAug 3

Top drivers: VIX percentile ▲ S&P vs 20d avg ▲ S&P vs 50d avg ▲

processId: history-market-regime

Market Indexes

Wed, Aug 12, 2026 13

S&P 500

7,748.50

+24.95

+0.32%

Dow Jones

53,770.27

−578.85

-1.07%

NASDAQ Composite

26,588.49

+225.05

+0.85%

NASDAQ 100

29,742.60

+254.81

+0.86%

DJ US Total Market

76,826.73

+389.52

+0.51%

Russell 1000

4,225.46

+21.10

+0.50%

S&P MidCap 400

3,898.99

+51.66

+1.34%

Russell 2000

3,045.48

+26.29

+0.87%

Russell 2500

1,299.68

+5.18

+0.40%

Russell 3000

4,412.26

+22.71

+0.52%

Nasdaq Financial-100

7,595.20

+49.62

+0.66%

NIFTY 50

24,435.95

−200.05

-0.81%

VIX

14.55

−0.60

-3.96%

Biggest Gainers

Wed, Aug 12, 2026 50

IVDA

Iveda Solutions, Inc.Industrials

$0.36+$0.26

+82.4%

NASDAQ · Mkt cap $4.2 M

Iveda announced a strategic partnership with GlobalMed to supply intelligent video surveillance and AI technology to government agencies, a material contract win that likely drove the 82% single-day surge in the micro-cap stock.

The partnership announcement with GlobalMed represents a concrete business development milestone for Iveda, a cloud-based AI video surveillance and smart infrastructure provider. For a micro-cap stock trading at $0.36, a named strategic partnership targeting government agencies constitutes significant validation and revenue potential. The timing of the announcement (same day as the price spike) and the specificity of the partnership (named partner, government sector focus) align directly with the magnitude of the move. Micro-cap technology stocks often exhibit outsized percentage moves on material contracts or partnerships, particularly those involving government clients, which typically signal revenue visibility and credibility. The 82% single-day gain is substantial but not anomalous for this class of security when backed by a credible business catalyst.

BIVI

BioVie Inc.Healthcare

$1.54+$0.92

+74.8%

NASDAQ · Mkt cap $10 M

No news headlines were found in the last 48 hours, so the 74.80% gain on BIVI cannot be attributed to a specific disclosed catalyst. The spike was likely driven by technical factors, rumor, or a delayed market reaction to an earlier announcement.

BioVie is a small-cap biotech stock trading on NASDAQ at $1.54, and the absence of recent news makes attribution difficult. For microcap biotech stocks, large single-day moves often stem from several possible sources: clinical trial results or regulatory updates that may not immediately appear in aggregated news feeds, short covering or technical breakouts if the stock had been heavily shorted or trading at support levels, social media or retail investor momentum, or delayed market digestion of older news. Without access to the company's investor relations channels, SEC filings, or real-time social media signals, we cannot isolate which of these factors drove today's move. The timing and magnitude suggest either a discrete event (favorable data, partnership announcement, or FDA action) that has not yet surfaced in the Yahoo Finance RSS, or a technically driven rally common in illiquid small-cap stocks.

GXAI

The NFT Gaming Company, Inc.Communication Services

$0.88+$0.54

+60.5%

NASDAQ · Mkt cap $9.2 M

Gaxos reported record second-quarter revenue up 35.8% sequentially and 1,337% year-over-year, with revenue growth outpacing advertising expense growth, likely driving the 60% gain as a micro-cap stock responds sharply to strong earnings.

The company announced record Q2 revenue with exceptional sequential and year-over-year growth rates. The headline explicitly emphasizes that revenue growth significantly outpaces advertising expense growth, indicating improving unit economics and margin expansion. For a micro-cap stock like GXAI trading under $1, earnings beats of this magnitude typically trigger outsized percentage moves because the float is small and retail investor participation can amplify price action. The metric showing revenue generated per advertising dollar improved suggests operational leverage is working, which addresses a key investor concern for growth-stage companies. However, the headline is truncated and does not provide absolute revenue figures, guidance, or forward commentary, limiting the completeness of the picture.

MYSEW

MYSEWTechnology

$0.01+$0.00

+60.0%

NASDAQ

Myseum.AI announced a partnership with major non-profit organizations to expand its Picture Party platform, reaching an estimated 1.6 million members, likely driving the 60% gain in this micro-cap stock on growth prospects.

The headline describes a user acquisition partnership between Myseum.AI and a coalition of 30+ non-profit organizations including Special Olympics, YMCA, Junior Achievement, and others with combined reach of over 1.6 million members. For a stock trading at $0.01, this type of partnership announcement—particularly one highlighting concrete distribution channels and user reach—can trigger significant percentage moves. The deal appears to expand the company's addressable market substantially and provides a path to rapid user growth without heavy customer acquisition costs. However, the headline is truncated and lacks key details such as revenue potential, exclusivity terms, or implementation timeline. At this price point, retail interest and technical factors (low float, penny stock dynamics) may amplify the move beyond what the fundamental news alone would suggest.

Boqii Holding LimitedConsumer Cyclical

$1.22+$0.44

+55.7%

NYSE · Mkt cap $7.2 M

BQ jumped 55.70% with no news headlines in the last 48 hours, suggesting the move may be driven by technical factors, short covering, or undisclosed corporate developments not yet reflected in public RSS feeds.

No headlines were found in the Yahoo Finance RSS feed for the last 48 hours covering BQ, which means the catalyst for this 55.70% rally is not immediately obvious from mainstream news sources. For a micro-cap stock like Boqii (a pet services company), large single-day moves are not uncommon and can be driven by several factors unrelated to major news: technical short squeezes or covering of heavily shorted positions, after-hours or pre-market announcements not yet widely syndicated, analyst upgrades or initiations, insider activity disclosures, or general retail/momentum trading. It is also possible that a material announcement was made but has not yet been picked up by major RSS feeds. Without corroborating headlines or structural information about the stock's short interest or float, attributing this move to a specific catalyst would be speculative.

BRUNW

Boost Run Inc. Warrant

$10.58+$3.55

+50.5%

CHOW

ChowChow Cloud International Holdings LimitedTechnology

$0.51+$0.15

+43.7%

NYSE · Mkt cap $14 M

No news headlines were available in the last 48 hours to explain the 43.73% gain in CHOW stock on August 12, 2026. The move likely reflects a technical bounce, delayed news, or market sentiment shift in a micro-cap security.

The absence of recent news headlines makes it impossible to link this substantial one-day rally to a specific corporate event such as earnings, guidance, partnerships, or regulatory approval. CHOW is a micro-cap stock trading at $0.51, which typically means higher volatility and greater susceptibility to technical factors, short covering, or retail sentiment shifts. Penny stocks and very low-priced equities often experience large percentage moves on modest dollar volume. Without corroborating news, this gain could reflect delayed dissemination of an announcement, algorithmic or options-driven positioning, a broader sector rally in cloud services, or accumulation by retail traders. The lack of headline evidence means the true catalyst remains unclear and may not be publicly disclosed yet.

BOXL

Boxlight CorpTechnology

$7.86+$1.84

+39.9%

NASDAQ · Mkt cap $3.5 M

Boxlight jumped 40% following the announcement of Q2 2026 financial results and a private placement closing on August 6, suggesting positive earnings or capital raise news drove investor enthusiasm.

Two catalysts arrived within 24 hours. On August 11, the company announced the closing of a private placement, which typically signals capital raising to fund growth or operations. On August 12, Boxlight released Q2 2026 financial results. The headlines provided do not include the actual figures, guidance, or qualitative commentary from the earnings release, so we cannot confirm whether results beat expectations, met them, or missed. However, the timing of a 40% rally concurrent with earnings publication suggests the market received the results positively. For a provider of interactive technology solutions, positive catalysts might include revenue acceleration, margin improvement, or upbeat forward guidance. The private placement may have also signaled investor confidence or been tied to a strategic initiative announced in the earnings call. Without the actual financial data or management commentary, we cannot rule out technical factors, short covering, or delayed news dissemination as secondary contributors.

DOGZ

Dogness International CorpConsumer Cyclical

$1.24+$0.37

+38.9%

NASDAQ · Mkt cap $17 M

No news headlines were found in the last 48 hours for DOGZ, so the 38.95% gain cannot be attributed to a specific announced catalyst. The jump was likely driven by technical factors, retail interest, or an undetected news event.

The absence of any Yahoo Finance headlines in the 48-hour window preceding this large single-day gain makes direct attribution impossible. DOGZ is a micro-cap stock trading at $1.24, a price range and market classification typical of securities that experience outsized percentage moves on modest absolute volume or technical triggers. For stocks in this category, gains of this magnitude can result from short covering, options-related gamma effects, social media momentum, sector rotation, or delayed news that may not yet be indexed in the headline feed provided. Without access to level-two order flow data, insider trades, or real-time social sentiment, identifying the specific catalyst remains speculative.

TCGX

TCGX Acquisition Corp.Financial Services

$17.50+$5.58

+38.7%

NASDAQ · Mkt cap $147 M

No news headlines were found in the last 48 hours, so the 38.7% jump in TCGX likely reflects either a SPAC-related corporate action, delayed announcement disclosure, or technical/speculative trading activity typical of blank-check acquisition vehicles.

TCGX is a SPAC (special purpose acquisition company), a structure designed to identify and merge with an operating business. The absence of recent headlines despite a substantial single-day gain suggests either a delayed news disclosure that has not yet propagated to the RSS feed, an internal corporate action such as a merger agreement announcement or shareholder vote outcome, or speculative repositioning ahead of an anticipated deal. SPACs are inherently event-driven and often experience sharp price moves on M&A catalysts or deal closure milestones. Without access to current SEC filings or company press releases outside the headline feed, it is not possible to confirm the specific trigger. The timing and magnitude are consistent with either positive deal news or a technical squeeze.

BANL

CBL International Limited - Ordinary SharesEnergy

$6.05+$1.57

+37.8%

NASDAQ · Mkt cap $26 M

No news headlines were published in the last 48 hours for BANL, so the 37.81% jump cannot be attributed to reported corporate events; the driver remains unknown based on available information.

CBL International Limited (BANL) surged 37.81% on August 12, 2026, ranking as the 11th biggest gainer of the day, yet no news headlines appear in the Yahoo Finance RSS feed for the preceding 48 hours. This disconnect between significant price movement and absent news coverage creates a genuine analytical gap. The jump could reflect several categories of catalyst: a delayed market reaction to an older announcement not captured in the recent headlines feed, technical or algorithmic trading activity responding to price levels or volume patterns, short covering if the stock trades with significant short interest, rumors or social media discussion not yet formalized into news, or changes in underlying fundamentals for the broader retail or consumer sector BANL operates in. Without access to real-time earnings releases, SEC filings, or insider information, the specific cause cannot be determined from the evidence provided.

FXHO

Utime Ltd.Technology

$13.56+$3.50

+34.8%

NASDAQ · Mkt cap $54 M

No news headlines were found in the last 48 hours for FXHO, so the 34.79% gain cannot be directly attributed to a specific reported event. The jump may reflect technical trading, delayed news dissemination, or market rumors not yet captured in major news feeds.

The absence of any recent news headlines creates significant uncertainty about the catalyst for this large single-day gain. FXHO is a relatively small-cap stock, and such moves in low-liquidity securities can be driven by several factors not immediately visible in mainstream financial news: a delayed earnings announcement or earnings surprise that has not yet been widely reported, short-squeeze activity among a concentrated shareholder base, technical chart breakout triggering algorithmic buying, or social media-driven retail interest. Without access to company filings, insider activity, or real-time market microstructure data, pinpointing the specific cause is not possible from the evidence provided. The rank as the 12th biggest gainer suggests broad market awareness, but the lack of corresponding headlines is unusual and indicates either very recent developments not yet indexed by news aggregators or a move driven primarily by technical or sentiment factors rather than fundamental news.

MVIS

MicroVision IncTechnology

$4.64+$1.09

+30.4%

NASDAQ · Mkt cap $42 M

No headlines were found in the last 48 hours, so the 30.42% gain cannot be directly attributed to reported news. The jump likely reflects technical strength, short-covering, or a delayed market reaction to an earlier announcement not captured in the RSS feed.

MicroVision is a microcap technology company focused on augmented reality and display technology, typically characterized by high volatility and periodic surges driven by product announcements, licensing deals, or strategic partnerships. The absence of news in the immediate 48-hour window prior to this snapshot does not rule out a catalyst occurring earlier or a technical trigger such as a breakout above resistance, options expiration gamma effects, or renewed short covering. For speculative, low-float equities like MVIS, volume spikes and momentum can compound gains independent of same-day news releases. It is also possible that material news was announced but not yet indexed in the Yahoo Finance RSS feed shown here, or that the announcement occurred on August 11 evening and the gain materialized on August 12 opening.

PTN

Palatin Technologies, Inc.Healthcare

$9.39+$2.22

+29.9%

NYSE · Mkt cap $18 M

No news headlines were found in the last 48 hours, so the 29.91% gain on PTN cannot be directly attributed to a specific announced catalyst; the move likely stems from technical factors, delayed news dissemination, or unconfirmed market rumors.

Palatin Technologies is a small-cap biopharmaceutical company with a history of volatile price swings tied to clinical trial results, regulatory decisions, or partnership announcements. The absence of any news in the Yahoo Finance RSS feed over the past 48 hours is notable given the magnitude of the move. For stocks in this sector and size category, sharp single-day rallies without concurrent headlines often reflect one of several patterns: a delayed or embargoed news release not yet broadly indexed, short-covering in a thinly traded name, technical breakout from a key support level, or market response to news reported through non-mainstream channels. Without access to press releases, company filings, or clinical trial databases, attributing this move to a specific event is not possible based on the evidence provided.

FEED

ENvue Medical, Inc.Healthcare

$0.41+$0.12

+29.4%

NASDAQ · Mkt cap $3.9 M

ENvue Medical announced a $50 million equity financing facility on August 12, which likely drove the 29.37% gain as investors responded positively to the capital raise supporting commercial growth, technology expansion, and strategic acquisitions.

The company announced today that it has secured an equity financing facility of up to $50 million, framed as supporting commercial growth, technology expansion, and strategic acquisitions. For a micro-cap medical technology company trading at $0.41, a $50 million capital facility represents a material event that signals financial runway and strategic optionality. The timing of the announcement (12:35 UTC on the same day as the price move) and the rank as the 15th biggest gainer suggest market participants viewed this as positive news. However, the headline excerpt is truncated and does not specify the terms, dilution impact, or whether this is a committed or conditional facility, which limits precision in analyzing investor motivation. The strength of the move suggests either the capital raise was better-received than expected or secondary factors (such as improvement in cash position, reduced bankruptcy risk, or anticipated use of capital for near-term milestones) drove incremental demand.

SION

Sionna Therapeutics, Inc. Common StockHealthcare

$6.27+$1.44

+29.3%

NASDAQ · Mkt cap $282 M

SION surged 29% on August 12, likely a technical bounce or short-covering rally after the stock collapsed 90%+ on August 10-11 following failure of its lead cystic fibrosis drug SION-719 in a Phase 2a trial.

The headlines establish that Sionna's SION-719 failed to meet its primary endpoint as an add-on therapy to Trikafta on August 10-11, triggering a catastrophic 90%+ crash. The August 12 gain of 29% occurred the day after this collapse. This pattern is typical of severely oversold biotech stocks: extreme sell-offs often trigger technical rebounds as short positions cover, algorithmic rebalancing occurs, or value-oriented traders view the depressed price as attractive despite the clinical failure. One headline from August 12 mentions the valuation "sits alongside a low overall value score," suggesting some investors may have viewed the crash as overdone. However, the headlines provide no new positive clinical, regulatory, or strategic news on August 12 itself, only retrospective analysis of the prior day's disaster. The bounce appears to be a technical or sentiment-driven reversal rather than a response to new company-positive information.

CANG

Cango Inc-KYFinancial Services

$2.22+$0.50

+29.0%

NYSE · Mkt cap $69 M

No news headlines were found in the last 48 hours, so the 29% jump on CANG appears driven by technical factors, market rumors, or a delayed announcement not yet captured in the RSS feed.

Cango Inc is a used-car transaction platform with a history of volatility typical of smaller-cap fintech and automotive-adjacent stocks. Without any news catalyst identified in the provided headlines, the substantial single-day gain could stem from several common drivers: a short squeeze or covering of heavily shorted positions, a technical breakout that triggered algorithmic buying, positive commentary from a major shareholder or analyst not yet syndicated to Yahoo Finance RSS, or an unconfirmed market rumor circulating on social media or trading forums. Smaller stocks like CANG often see outsized intraday moves on thin volume with minimal fundamental justification. The absence of news does not rule out a legitimate catalyst; it may simply mean the announcement has not yet been indexed by the RSS feed used here or was released through alternative channels.

XHLD

TEN Holdings, Inc. Common StockCommunication Services

$5.33+$1.12

+27.7%

NASDAQ · Mkt cap $92 M

TEN Holdings reported Q2 2026 financial results on August 10, and the market reacted positively with a 27.65% gain, likely driven by results that met or exceeded expectations or positive forward guidance from the event technology company.

The company released second quarter 2026 financial results on August 10, 2026, just two days before this snapshot. The headline confirms the earnings announcement occurred but does not provide specific details about whether results beat or missed estimates, guidance changes, margin improvements, or revenue growth rates. For an event technology company serving enterprise customers with virtual and hybrid solutions, positive catalysts could include strong bookings, margin expansion, or improved forward guidance reflecting post-pandemic stabilization or cloud adoption tailwinds. The timing and magnitude of the gain (18th biggest mover) suggests the market viewed the results or commentary favorably, but without access to the actual earnings release details, we cannot isolate the specific metric driving the enthusiasm.

QNT

Quantinuum Inc.Technology

$71.75+$15.46

+27.5%

NASDAQ · Mkt cap $13 B

Quantinuum surged 27% on its first post-IPO earnings beat combined with a major Oracle partnership announcement to integrate quantum computing into Oracle Cloud Infrastructure, plus a system sale to Oracle.

The headlines establish three concrete catalysts. First, Quantinuum reported Q2 2026 revenue of $8 million, up 279% year-over-year, beating analyst estimates in its inaugural earnings report as a public company (IPO in June). Second, on the same day Oracle announced a multi-year partnership to bring quantum computing to Oracle Cloud Infrastructure, representing a major validation and commercial win for Quantinuum technology. Third, Oracle is purchasing a Quantinuum system as part of this deal. While the company's GAAP net loss widened to $597 million, early-stage quantum computing companies are typically valued on revenue growth trajectory and strategic partnerships rather than near-term profitability. The combination of an earnings beat, a Fortune 500 partnership, and demonstrated commercial adoption (system sale) explains the sharp move in what is still an early-stage, high-growth technology stock. The quantum computing sector itself is gaining momentum on AI compute strain and federal funding support.

MYSZ

My Size IncConsumer Cyclical

$0.40+$0.10

+27.0%

NASDAQ · Mkt cap $1.7 M

MySize announced a reverse stock split on August 10, which likely triggered the 27% gain as such announcements often spark short-covering and retail momentum trading, particularly in low-priced stocks.

The only headline provided is a reverse stock split announcement from August 10. The news item is truncated and does not specify the split ratio or provide additional context from the full release. Reverse stock splits are typically announced to maintain minimum listing requirements or improve stock price optics, and they frequently generate trading activity in thinly traded microcap stocks like MYSZ. Given that MYSZ trades at $0.40 and ranks among the day's top twenty gainers, the move appears mechanically consistent with a reverse split announcement sparking short covering and retail interest. However, the incomplete headline text leaves open the possibility that additional details in the full announcement—such as financing news, partnership announcements, or operational updates embedded in the same release—may have contributed to the spike. Without access to the complete press release, we cannot rule out other catalysts announced simultaneously.

SCNX

Scienture Holdings, Inc.Healthcare

$0.44+$0.10

+25.3%

NASDAQ · Mkt cap $19 M

Scienture announced the commercial launch of REZENOPY, its FDA-approved 10 mg naloxone nasal spray, and fulfilled initial purchase orders, triggering a 25% rally as the company moves into active revenue-generating operations.

All three headlines from the past 48 hours document the same pivotal event: Scienture's official commercial launch of REZENOPY on August 12, 2026. The company positioned it as the highest-dose FDA-approved naloxone nasal spray and confirmed it has already fulfilled initial purchase orders. The launch is supported by a dedicated national sales force, payer and institutional access agreements, and a multi-channel marketing campaign. For a small-cap pharmaceutical company with a market price of $0.44, the transition from development to commercial execution with an already-approved product and initial sales fulfillment represents a material de-risking event. The 25% single-day gain aligns with typical market responses to milestone catalysts in biotech, particularly when a company demonstrates proof of commercial execution rather than merely announcing regulatory approval. No competing headlines or contradictory news appears in the record.

FWACW

Futurewave Acquisition Corporation Warrants

$0.05+$0.01

+24.8%

OMER

Omeros CorpHealthcare

$13.68+$3.19

+23.6%

SCKT

Socket Mobile IncTechnology

$1.60+$0.32

+23.4%

NASDAQ · Mkt cap $5.6 M

No headlines were found in the last 48 hours to explain Socket Mobile's 23.36% jump. The move likely stems from technical trading, delayed news release, or retail attention to a micro-cap stock.

Socket Mobile is a small-cap technology company, and no recent news headlines are available to account for the significant single-day gain of over 23 percent. In the absence of identifiable fundamental catalysts such as earnings releases, product announcements, or strategic partnerships, the move is most likely driven by one of several common drivers for micro-cap stocks: technical breakout or short covering, retail trading volume concentration, or delayed disclosure of an announcement not yet reflected in the RSS feeds checked. Small-cap stocks with low float and liquidity can experience outsized percentage moves on relatively modest volume. It is also possible that news was released but has not yet propagated through major financial RSS feeds, or that the move reflects market reaction to broader sector momentum rather than company-specific factors.

INBS

Intelligent Bio Solutions Inc.Healthcare

$2.54+$0.48

+23.3%

NASDAQ · Mkt cap $8.1 M

Intelligent Bio Solutions announced completion of its FDA 510(k) clinical study for its drug screening system with FDA submission targeted for H2 2026, validating progress on a key regulatory milestone that likely triggered the 23% surge.

The company disclosed on August 11 that all clinical data collection for its Intelligent Fingerprinting Drug Screening System FDA 510(k) program is complete and that submission remains on track for the second half of 2026. This represents a concrete milestone in the product development cycle—the transition from data collection to regulatory filing—which removes a key execution risk for investors. For a small-cap biotech or diagnostic device company with limited revenue streams, advancement toward FDA clearance typically drives material re-rating because it de-risks commercialization prospects and can unlock significant market opportunity if cleared. The timing of the announcement and the stock's position as a 25 gainer suggest the market had been awaiting this validation. No competing news or contradictory headlines appear in the provided feed.

DDC

DDC Enterprise LimitedConsumer Defensive

$0.59+$0.11

+23.1%

NYSE · Mkt cap $27 M

No news headlines were found in the last 48 hours, so the 23% gain on DDC likely reflects technical trading, delayed news dissemination, or market speculation rather than a confirmed catalyst.

DDC Enterprise Limited gained 23.12% to close at $0.59 on August 12, 2026, but Yahoo Finance carried no headlines about the stock in the prior 48 hours. This absence of contemporaneous news coverage makes it difficult to pinpoint a specific fundamental driver. At this price point and likely market capitalization, DDC may be susceptible to several categories of moves: technical bounce-backs after prior weakness, retail trading interest or social media discussion that precedes formal news pickup, delayed disclosure of company announcements that have not yet reached major wire services, or sector-wide momentum. Without access to regulatory filings, internal company releases, or real-time trading data, we cannot distinguish between these scenarios. The lack of headline coverage does not rule out a genuine corporate event; it simply means the reason is not yet evident from the sources provided.

CURI

CuriosityStream Inc.Communication Services

$2.79+$0.64

+22.9%

NASDAQ · Mkt cap $173 M

CuriosityStream reported record Q2 earnings with $8.9 million net income, 22% revenue growth to $23.2 million, and raised full-year guidance, driving the 23% gain.

The headline establishes a clear earnings catalyst: CuriosityStream delivered better-than-expected Q2 results highlighted by record net income of $8.9 million and strong adjusted EBITDA of $11.4 million. Revenue grew 22% year-over-year to $23.2 million, with licensing revenue particularly strong at $14.1 million (up 48%), indicating successful new partnership monetization. Management raised full-year revenue and adjusted EBITDA guidance, signaling confidence in sustained momentum. For a smaller-cap streaming and content company trading at $2.79, a profitable quarter with accelerating licensing growth and raised guidance represents a material positive inflection that typically justifies a sharp single-day move upward, particularly if prior market sentiment had been cautious.

HWH

HWH International IncConsumer Cyclical

$1.63+$0.30

+22.6%

NASDAQ · Mkt cap $16 M

No news headlines were found in the last 48 hours for HWH International Inc, so the 22.56% gain cannot be directly attributed to a disclosed catalyst. The move likely reflects technical factors, delayed news dissemination, or market-driven interest in the micro-cap stock.

The absence of any recent news coverage in the 48-hour window surrounding this substantial single-day gain makes it difficult to pinpoint a specific catalyst. HWH International trades on NASDAQ as a relatively small-cap security, and stocks in this category sometimes experience sharp moves on thin volume driven by technical trading, options-related activity, short covering, or retail investor interest rather than fundamental news. It is also possible that relevant news exists but was not captured by the Yahoo Finance RSS feed, or that an announcement occurred during market hours without immediate broad distribution. Without access to company filings, press releases, or trading volume data, the underlying cause remains speculative.

HLIT

Harmonic IncTechnology

$12.00+$2.56

+22.0%

NASDAQ · Mkt cap $1.3 B

Harmonic announced Q2 2026 earnings on August 12, and the stock jumped 22% the same day, likely driven by results that met or exceeded expectations or bullish forward guidance, combined with renewed momentum in optical component stocks tied to AI spending confidence.

Harmonic released its second quarter 2026 earnings on the morning of August 12, which coincides precisely with the stock's 22% gain that day. The timing strongly suggests the earnings announcement was the primary catalyst. Additionally, a Bloomberg report from the same day notes that optical component makers are experiencing a broad sector resurgence driven by rising confidence in artificial intelligence spending, which would amplify a positive earnings reaction for a company in that space. The headline does not disclose specific earnings metrics, margins, or guidance details, so the exact nature of the beat or positive surprise cannot be confirmed from the provided news. However, the combination of company-specific earnings and favorable sector momentum makes a compelling case for the move.

SMWB

Similarweb Ltd.Technology

$8.80+$1.57

+21.7%

NYSE · Mkt cap $737 M

Similarweb reported Q2 earnings and revenue above consensus expectations, raised full-year 2026 guidance, and cited larger enterprise contracts and improved retention, driving a 21.72% gain on the day.

The headlines establish that Similarweb delivered a 100% earnings surprise and 2.23% revenue surprise for Q2 2026, with year-over-year revenue growth of 9%. The company raised its full-year outlook and management highlighted larger enterprise contracts, improving retention rates, and rising demand for its digital data and analytics services. Premarket trading showed a 17% jump immediately following the earnings announcement at 12:10-13:40 UTC, with the stock adding another 4-5 percentage points through the close. The earnings beat combined with forward guidance raise suggests investor confidence in the company's growth trajectory and operational execution, particularly given the emphasis on enterprise contract expansion and customer retention improvements in a competitive SaaS environment.

SBEV

Splash Beverage Group, Inc.Consumer Defensive

$0.40+$0.07

+21.6%

NYSE · Mkt cap $2.5 M

Splash Beverage Group announced a rebrand to Endovia Health Sciences and strategic pivot into cannabinoid health sciences, triggering a 21.63% single-day gain likely driven by investor enthusiasm for the cannabis sector shift and perceived growth opportunity.

The company announced on August 12, 2026 that it is rebranding from Splash Beverage Group to Endovia Health Sciences, positioning itself as a diversified cannabinoid health sciences platform rather than a traditional beverage company. This represents a material strategic pivot that would appeal to investors seeking exposure to the cannabis industry, particularly those betting on cannabinoid-based health products. The timing and magnitude of the jump suggest the market views this repositioning as value-accretive. However, the headline excerpt provided does not include specific financial details, partnership announcements, or product pipeline information that would fully substantiate the move, so the gain likely reflects initial market sentiment around the strategic direction rather than detailed business fundamentals.

NBIS

Nebius Group N.V.Communication Services

$259.14+$44.80

+21.5%

NASDAQ · Mkt cap $61 B

Nebius reported second-quarter earnings with AI revenue surging 454% and over $40 billion in customer commitments, beating expectations and triggering a broad AI infrastructure rally that lifted the stock approximately 21-34% on the day.

The headlines establish a clear and specific catalyst: Nebius released Q2 earnings on August 12, 2026, that substantially exceeded consensus expectations. Multiple sources confirm AI revenue grew 454% year-over-year, and the company secured more than $40 billion in customer commitments for future capacity. This beat appears to have reignited confidence in the "neocloud" sector, with fellow infrastructure provider CoreWeave also posting better-than-expected results. The rally was compounded by short-covering dynamics, as noted in references to Michael Burry's short position coming under pressure as the earnings thesis contradicted bearish bets. The magnitude of the move reflects both the earnings surprise itself and the momentum effect across the entire AI data center infrastructure complex on a single day.

NXTC

NextCure IncHealthcare

$8.24+$1.45

+21.4%

NASDAQ · Mkt cap $31 M

No news headlines were found in the last 48 hours, so the cause of the 21.35% gain is unclear; this type of move in a biotech stock likely reflects either clinical trial results, regulatory news, or partnership announcements that have not yet appeared in the RSS feed.

NextCure is a clinical-stage immunotherapy company, and a 21.35% single-day jump of this magnitude typically correlates with meaningful catalysts such as positive clinical trial data, FDA regulatory decisions, partnership announcements, or financing news. The absence of headlines in the Yahoo Finance RSS feed over the last 48 hours suggests either that the news has not yet been indexed by this particular feed, that the move is delayed reaction to older news, or that the catalyst originated from a non-traditional source. For a small-cap biotech stock, internal company announcements, investor presentations, or pre-market regulatory filings can sometimes drive significant moves before appearing in mainstream news aggregators. Without access to the actual news content or timing, the exact driver cannot be established from the evidence at hand.

SHAZ

SharonAI Holdings Inc.Technology

$68.53+$11.92

+21.1%

NASDAQ · Mkt cap $2.0 B

No news headlines were published in the last 48 hours covering SHAZ, so the 21% single-day gain cannot be attributed to a specific disclosed event. The move likely reflects either a delayed market reaction to an untracked announcement, technical buying, or retail interest.

The absence of recent news coverage is notable given the stock's strong ranking as the 34th biggest gainer on a single day with a 21% move. This suggests the catalyst either occurred outside the monitored news feed, was not immediately picked up by major financial news outlets, or the move was driven by factors other than disclosed corporate events such as options positioning, short covering, or retail trading activity. For an AI-focused company like SharonAI Holdings, typical catalysts would include earnings surprises, product announcements, partnership agreements, or sector-wide enthusiasm for AI stocks. Without headline confirmation, we cannot determine which mechanism is at work here. The magnitude of the move warrants investigation into company filings, social media activity, or other real-time data sources not captured in this snapshot.

GRWG

GrowGeneration CorpConsumer Cyclical

$1.79+$0.31

+20.5%

NASDAQ · Mkt cap $106 M

GrowGeneration reported Q2 earnings on August 11 with proprietary brand penetration hitting 40%, positive adjusted EBITDA swung positive, and the company raised full-year adjusted EBITDA guidance, driving the 20.54% jump.

The stock's sharp gain is grounded in a successful earnings report released late on August 11. The company beat revenue estimates by 0.48% and delivered a 25% earnings surprise. Most significantly, GrowGeneration achieved positive adjusted EBITDA of $0.3 million after previously running losses, while proprietary brand penetration reached 39.7% to 40% of cultivation revenue, exceeding management's target early. This margin expansion via higher-margin proprietary products combined with improved profitability metrics and a raised full-year adjusted EBITDA guidance to $2 million to $3 million collectively signal execution on the company's transformation strategy. For a small-cap hydroponics supplier that has struggled with profitability, these operational inflection points and forward guidance hikes typically justify meaningful positive repricing.

SPCM

Sound Point Acquisition Corp I, LtdFinancial Services

$16.93+$2.84

+20.1%

RSKD

Riskified Ltd.Technology

$6.31+$1.04

+19.6%

NYSE · Mkt cap $813 M

Riskified beat Q2 revenue expectations with 22% YoY growth—its fastest in four+ years—and raised full-year guidance, triggering the 19.6% surge as the market reassessed growth prospects.

The earnings release on August 12 shows Riskified delivered revenue of $98.7 million, exceeding Wall Street expectations and representing accelerating growth well above prior quarters. The company also raised its full-year 2026 guidance following the strong quarter, which typically signals management confidence in sustained momentum. While the headlines note an earnings-per-share miss of 33%, the revenue beat and guidance raise appear to have dominated investor sentiment, particularly for a growth-stage fintech company where top-line acceleration and forward guidance changes often outweigh near-term profitability shortfalls. The premarket jump of 7% suggests institutional recognition, with the full-day 19.6% gain reflecting retail participation as the news widened distribution.

GSIW

Garden Stage LimitedFinancial Services

$18.58+$3.03

+19.5%

NASDAQ · Mkt cap $25 M

No news headlines were found in the last 48 hours for GSIW, so the 19.49% gain cannot be attributed to a documented corporate announcement or market event. The move likely reflects technical trading, delayed news pickup, or market rumor.

The absence of any recent news coverage for GSIW in the 48-hour window prior to this +19.49% jump makes direct attribution impossible. Garden Stage Limited is a smaller-cap NASDAQ stock, and such names can experience sharp intraday moves for several reasons: short covering if the stock had elevated short interest, algorithmic or retail-driven technical buying after a breakout of a resistance level, delayed dissemination of company news or regulatory filings not yet reflected in major RSS feeds, or speculation ahead of an upcoming earnings date or event announcement. Without access to order flow, insider trading activity, or real-time social media sentiment, we cannot determine which mechanism drove today's move. The lack of news coverage within 48 hours does not rule out a catalyst; it simply means the evidence is not available in the provided data set.

dMY Squared Technology Group, Inc.Technology

$14.97+$2.40

+19.4%

NASDAQ · Mkt cap $905 M

No news headlines were found in the last 48 hours for HQ, so the 19.35% gain likely reflects either delayed market reaction to an untracked announcement, technical trading activity, or general SPAC sector momentum rather than a specific identifiable catalyst.

The absence of any headlines in Yahoo Finance's RSS feed for the past 48 hours makes it impossible to attribute this significant 19.35% gain to a specific company event such as earnings, guidance, M&A activity, or regulatory news. dMY Squared Technology Group is a SPAC (special purpose acquisition company), which means this stock historically has been sensitive to deal rumors, de-SPAC timing announcements, or shifts in investor sentiment toward blank-check vehicles. The jump could reflect a delayed market reaction to news published outside the tracked headline window, technical trading around support or resistance levels, short covering, or sector-wide momentum in SPACs. Without visible news, attribution remains speculative.

BRUN

Boost Run Inc.Technology

$22.17+$3.56

+19.1%

NASDAQ · Mkt cap $1.4 B

No news headlines were found in the last 48 hours to explain BRUN's 19.13% surge, so the cause remains unclear without additional context or delayed reporting.

The absence of recent news is noteworthy given the stock's sharp 19.13% gain on 2026-08-12, ranking it among the day's top 40 gainers. A move of this magnitude typically correlates with identifiable catalysts such as earnings surprises, product announcements, partnership deals, or analyst upgrades. Without headlines in the provided 48-hour window, several common explanations warrant consideration: first, a delayed news distribution lag where an announcement may have occurred but not yet appeared in the RSS feed; second, a technical or momentum-driven rally, particularly if BRUN has been accumulating buying pressure or is held by a concentrated shareholder base; third, sector-wide tailwinds if running and athletic apparel is in favor on the trading day. Alternatively, the move could reflect a response to after-hours news or rumor not yet captured in mainstream reporting. The lack of evidence prevents confident attribution to any specific event.

MRX

Marex Group plcFinancial Services

$71.17+$11.24

+18.8%

NASDAQ · Mkt cap $5.2 B

Marex Group delivered a strong Q2 earnings beat with record profit and revenue growth across its core businesses, beating earnings estimates by over 20% and revenue estimates by over 18%, which drove the 18.76% stock surge.

The headlines establish a clear consensus around the earnings catalyst. Marex reported record second-quarter profit with a 20.59% earnings surprise and 18.13% revenue surprise versus consensus estimates. The company achieved revenue growth across clearing, agency and execution, market-making, and solutions businesses despite headwinds from lower exchange volumes. The earnings call and multiple reports on August 12 all frame this as a strong result that "blew past" expectations and triggered a technical buy signal. The market repricing reflects confidence in the company's diversified revenue streams and profitability. No guidance changes, M&A, or other catalysts are mentioned, so the move is attributable solely to the earnings beat and the positive operational narrative around business segment performance.

USDEW

StablecoinX Inc. Warrants

$0.51+$0.08

+18.5%

GCDT

Green Circle Decarbonize Technology LimitedIndustrials

$0.49+$0.08

+18.3%

NYSE · Mkt cap $5.2 M

No news headlines were reported in the last 48 hours for GCDT, so the 18.27% gain cannot be traced to a disclosed catalyst; the move likely reflects technical trading, delayed news dissemination, or market speculation.

The absence of any Yahoo Finance headlines in the past two days makes it impossible to attribute GCDT's strong 18.27% rally to a specific fundamental or event-driven catalyst. For a micro-cap green technology stock trading at $0.49, moves of this magnitude are not uncommon and can be driven by several factors. The most likely categories are technical in nature—such as short-covering, algorithmic buying triggered by price action or volume thresholds, or retail momentum trading—or stem from news that has not yet propagated to major financial RSS feeds. Alternatively, an announcement may have occurred outside the monitored news window or on the company's own channels before reaching broader distribution. Without headline evidence or knowledge of GCDT's specific structure or insider activity, pinpointing the precise cause is not feasible.

WTGUR

Wintergreen Acquisition Corp. Rights

$0.16+$0.02

+18.1%

NASDAQ

No news headlines were available in the last 48 hours, so the 18% gain in WTGUR rights likely reflects either technical/speculative activity typical of low-priced securities or unreported developments in the parent SPAC's merger negotiations.

Wintergreen Acquisition Corp. Rights are a derivative security tied to the underlying SPAC's warrant or equity value. Rights offerings typically experience outsized percentage moves on modest dollar swings due to their low absolute price, and without any reported news, this gain most likely reflects either algorithmic trading in a thinly-traded security, retail speculation, or an unreported development in Wintergreen's acquisition target or merger timeline. SPAC rights are particularly sensitive to sentiment around deal closure probability and warrant-exercise mechanics. It is also possible that news was released but not yet indexed by the RSS feed, or that the move was driven by technical factors such as short covering or rebalancing. Without substantive headline confirmation, attribution remains speculative.

PESI

Perma-Fix Environmental ServicesIndustrials

$19.43+$3.09

+17.9%

NASDAQ · Mkt cap $368 M

Perma-Fix announced it won a Master IDIQ subcontract from Hanford Tank Waste Operations for grouting and disposal of mixed low-level waste, with task orders eligible to begin January 2027 through December 2041, driving the 17.85% gain.

The stock surged on concrete contract news released on earnings day. Perma-Fix secured a Master Indefinite Delivery/Indefinite Quantity subcontract under a larger $4.37 billion Hanford program, with work to be performed at its Richland, Washington facility. The ordering period spans 15 years (2027-2041), suggesting substantial long-term revenue potential, though the headlines do not disclose the contract's total value or expected annual task order volume. The company also reported Q2 2026 results and commencement of DFLAW waste receipts on the same day. The 17.85% jump reflects investor enthusiasm for the secured long-duration business pipeline in the environmental remediation sector, a capital-intensive field where such multi-year government contracts are valuable. No earnings beat or miss is explicitly mentioned in the provided headlines.

MBRX

Moleculin Biotech IncHealthcare

$0.51+$0.08

+17.8%

NASDAQ · Mkt cap $4.3 M

No news headlines were found in the last 48 hours, so the 17.82% gain likely reflects technical trading, a delayed market reaction to an earlier announcement, or sector-wide momentum in biotech stocks.

Moleculin Biotech is a small-cap biotech company, and the absence of any news in the Yahoo Finance RSS feed in the last 48 hours makes it difficult to identify a specific catalyst for the 17.82% gain. Small biotech stocks are frequently subject to technical rebounds after sell-offs, short-covering, or accumulation by retail traders. The stock's low price of $0.51 makes it sensitive to percentage swings on relatively modest volume. Alternatively, the move could reflect a delayed market reaction to news that did not propagate through the major RSS feeds, or it could be part of a sector-wide rally in biotech. Without direct evidence of a specific event—such as clinical trial results, partnership announcements, or regulatory filings—any explanation remains speculative.

IPEXR

Inflection Point Acquisition Corp. V

$0.54+$0.08

+17.4%

NASDAQ

No headlines were published in the last 48 hours, so the 17.35% gain on IPEXR likely stems from either technical trading activity, a delayed market reaction to an earlier announcement, or typical SPAC volatility rather than fresh news.

With zero headlines in the recent news feed, we cannot identify a specific catalyst from public announcements. IPEXR is a blank-check company (SPAC), a security class known for sharp intraday moves driven by thin liquidity, retail trading activity, or delayed reactions to previous news cycles. At $0.54, the stock is trading near typical SPAC liquidation or dissolution thresholds, making it sensitive to any shift in market perception regarding merger prospects, extension votes, or redemption dynamics. The 17.35% move could reflect profit-taking reversal, short covering, or momentum chasing in a low-price, low-float name. Without accompanying news, we cannot distinguish between these mechanical explanations and any fundamental catalyst.

ZJYL

JIN MEDICAL INTERNATIONAL LTD. - Ordinary SharesHealthcare

$3.45+$0.51

+17.3%

NASDAQ · Mkt cap $24 M

No news headlines were available in the last 48 hours to explain ZJYL's 17.35% jump, so the catalyst remains unclear; typical candidates for this type of move include delayed news dissemination, technical rebounds, or unconfirmed rumors.

The lack of any news headlines in the Yahoo Finance RSS feed for the past 48 hours leaves the driver of this significant intraday gain unexplained by publicly available reporting at the time of analysis. A 17.35% move is substantial and typically associated with material corporate events such as earnings surprises, clinical trial results, regulatory approvals, financing announcements, or strategic partnerships. For a smaller-cap biomedical firm like Jin Medical International, moves of this magnitude often correspond to clinical or regulatory developments, acquisition rumors, or short-covering in a thinly traded security. Without documented headlines, this could represent a delayed market reaction to older news, technical rebound from oversold levels, or information spreading through channels not captured in standard news feeds. The absence of confirmatory reporting makes definitive attribution impossible.

ATRO

Astronics CorpIndustrials

$87.88+$12.95

+17.3%

NASDAQ · Mkt cap $3.2 B

Astronics reported record Q2 2026 earnings with 27% revenue growth, raised full-year guidance above $1 billion, and posted margin expansion to 19.8%, directly catalyzing the 17% single-day jump.

On August 11-12, Astronics released second-quarter 2026 results that exceeded expectations across multiple dimensions. The company posted record revenue of $260 million, up 27% year-over-year, alongside record bookings and backlog. Critically, adjusted EBITDA margins expanded to 19.8%, demonstrating operational leverage. Management raised full-year 2026 revenue guidance to $1.02–$1.04 billion, crossing the $1 billion threshold for the first time. The earnings call also highlighted tailwinds from stronger aerospace demand, production efficiencies, pricing actions, and an Army radio test ramp supporting second-half momentum. These fundamentals—record results, margin gains, guidance raise, and visible forward catalysts—align cleanly with the stock's 17% move, which was already partially anticipated in a 13.4% jump on initial earnings release. The stock has roughly doubled in 2026 year-to-date, consistent with strong sustained execution.

SOS

SOS LimitedFinancial Services

$0.89+$0.13

+17.0%

NYSE · Mkt cap $17 M

No news headlines appeared in the last 48 hours to explain SOS's 16.97% gain, so the move likely stems from technical trading, short covering, or delayed disclosure of an undisclosed event.

Yahoo Finance returned no headlines for SOS Limited in the 48 hours preceding the 16.97% rally on August 12, 2026. Without news, the driver cannot be pinpointed to a specific corporate action, earnings result, or regulatory event. SOS is a cryptocurrency mining and blockchain company historically subject to sharp moves driven by bitcoin price swings, short-squeeze dynamics, or sentiment shifts in the crypto sector. The stock trades at a very low price ($0.89), which can amplify percentage moves on modest absolute volume. Possible explanations include a rebound in bitcoin or the broader crypto market, covering of short positions, or an undisclosed press release or regulatory filing that has not yet propagated to major news feeds. Without corroborating headlines or data on market conditions on that date, any explanation remains speculative.

Biggest Losers

Wed, Aug 12, 2026 50

AACI

Armada Acquisition Corp. IFinancial Services

$2.68−$7.32

-73.2%

NASDAQ · Mkt cap $341 M

No news headlines were found in the last 48 hours to explain AACI's 73% collapse, making the cause impossible to determine from available evidence.

Armada Acquisition Corp. I is a SPAC, a blank-check company that typically trades near $10 net asset value with limited volatility until a merger or deal is announced or fails. A 73% single-day drop to $2.68 on zero reported news is highly unusual and suggests either a delayed major announcement (deal failure, merger collapse, insider departure) that hasn't yet appeared in the Yahoo Finance feed, a technical issue or trading halt reversal, or significant after-hours developments from yesterday that are not yet reflected in headline searches. For SPACs, the most common catalysts for such extreme moves are failed merger negotiations, shareholder votes rejecting a deal, liquidity or sponsor issues, or regulatory rejection of a proposed transaction. Without confirmed headlines, this remains pure speculation based on the security type and the magnitude of the move.

SLXN

Biomotion SciencesHealthcare

$0.45−$0.58

-56.2%

NASDAQ · Mkt cap $540 K

Silexion Therapeutics announced a $2.5 million public offering on August 11, which typically causes sharp dilution-driven selloffs in early-stage biotech stocks, explaining the 56% single-day decline.

The headline confirms that Silexion Therapeutics (NASDAQ: SLXN) priced a $2.5 million public offering on August 11, 2026. In clinical-stage biotechnology companies, equity offerings at this scale relative to market cap trigger immediate negative reactions because they represent substantial shareholder dilution. Investors price in the dilution instantly and often interpret small offerings as a sign of cash burn concerns or inability to secure more favorable funding terms. The timing of the announcement coinciding with the 56% drop on August 12 makes causation highly plausible. No other news items are present in the recent headlines to suggest alternative drivers. The magnitude of the decline is consistent with biotechnology sector patterns following dilutive equity raises, particularly for companies with limited clinical-stage cash runways.

BAOS

Baosheng Media Group Holdings Limited Ordinary sharesCommunication Services

$0.74−$0.89

-53.7%

NASDAQ · Mkt cap $799 K

No news headlines were found in the last 48 hours to explain BAOS's 53.70% single-day crash, making the specific cause unclear; the move likely stems from a delisting warning, reverse split announcement, or other corporate action not yet reflected in available news feeds.

The absence of any news in the Yahoo Finance RSS feed over the last two days is notable given the severity of the move. A 53.70% single-day plunge in a NASDAQ-listed stock typically requires a material catalyst. For microcap or distressed equities like BAOS trading at $0.74, common triggers include delisting notices from the exchange, reverse stock split announcements, failed financing attempts, insider selling disclosures, or regulatory setbacks. It is also possible that news was published outside the RSS feed window or that market rumors circulated without formal press releases. Without access to the company's investor relations page, SEC filings, or broader financial news sources beyond the provided headlines, pinpointing the exact cause remains speculative.

ALCE

Alternus Clean Energy, Inc.Utilities

$0.06−$0.05

-42.9%

NASDAQ · Mkt cap $43 K

No news headlines were found in the last 48 hours, so the 42.86% drop cannot be directly attributed to a specific announced event. The decline likely stems from technical selling, market sentiment, or unannounced developments affecting this microcap clean energy stock.

Alternus Clean Energy is a microcap renewable energy company trading at $0.06, and despite a dramatic single-day loss of 42.86% ranking it among the top four losers on NASDAQ, no financial news, earnings releases, regulatory actions, or corporate announcements appear in the available headline sources within the last 48 hours. This disconnect between a severe price move and absent news is common in illiquid, low-priced equities where trading volume can be thin and price movements may reflect technical factors such as stop-loss cascades, short covering, or algorithmic selling rather than fundamental catalysts. Alternative explanations for this stock class might include delayed disclosure of adverse developments, sector-wide pressure on renewable energy equities, or deterioration in sentiment toward microcap cleantech names, but these remain speculative without corroborating headlines or data.

NCMI

National CineMedia IncCommunication Services

$2.22−$1.59

-41.7%

NASDAQ · Mkt cap $248 M

National CineMedia plunged 41.7% despite announcing a $275 million acquisition of Captivate Network and reporting 12.7% revenue growth, likely because the company missed EPS estimates by 11.11% and the market views the large acquisition as dilutive or overly ambitious given current profitability …

The headlines present a mixed picture. On the positive side, NCMI reported 12.7% revenue growth, theater attendance increased, and advertising sales rose in Q2 2026. The company also announced a definitive agreement to acquire Captivate Network for $275 million, positioning itself as a leading digital out-of-home advertising platform. However, the earnings surprise was significantly negative: NCMI reported a loss for Q2 and missed EPS estimates by 11.11%, while also falling short on revenue by 3.31%. The severe 41.71% drop suggests investors are deeply concerned about the company's profitability trajectory and the timing or terms of the $275 million acquisition. The deal may be viewed as financially overextended or risky given the current operating losses, regardless of strategic merit.

LESL

Leslie''s IncConsumer Cyclical

$1.29−$0.51

-38.1%

NASDAQ · Mkt cap $6.1 M

Leslie's reported Q2 2026 revenue of $458.5 million, down 8.4% year-over-year and below analyst expectations, along with non-GAAP EPS 21.8% below estimates, triggering a 42.9% intraday drop.

The earnings announcement on August 12 clearly established the primary catalyst for the stock's collapse. Leslie's, a pool products retailer, missed on both top-line and bottom-line metrics in Q2 2026. Revenue declined year-over-year at a time when investors likely expected growth or stability, and earnings per share fell significantly short of consensus forecasts at $3.96 versus expectations roughly 5% higher. The combination of negative revenue momentum and earnings miss typically triggers sharp sell-offs in consumer discretionary stocks, particularly in sectors tied to seasonal demand and outdoor leisure spending where visibility is presumed high. The timing of the earnings release appears to have driven the stock from prior closing levels to $1.29, representing the sixth-largest percentage decline on the exchange that day. No offsetting guidance improvement or strategic announcement was mentioned in the available headlines.

SNAL

Snail, Inc.Communication Services

$2.89−$1.70

-37.0%

NASDAQ · Mkt cap $26 M

Snail reported a Q2 loss and missed revenue estimates by 32%, explaining the 37% stock plunge despite analyst upgrades and optimistic forward guidance about pipeline and AAA titles.

On August 11, Snail reported second-quarter financial results that included a net loss and revenue that fell 32% short of expectations, generating a -216% earnings surprise. This miss is the primary near-term driver of the sharp sell-off. Notably, the same day brought analyst coverage from Noble Financial reiterating an Outperform rating and highlighting ARK franchise momentum and new AAA game titles in development, plus company commentary about a strong second-half setup. The disconnect between backward-looking poor results and forward-looking optimism is common in growth-stage entertainment and gaming stocks. Investors appear to be punishing the recent miss more heavily than they are crediting near-term pipeline promises, likely reflecting skepticism about execution risk or concern that revenue guidance embedded in guidance was already implying recovery.

CRIS

Curis IncHealthcare

$1.66−$0.85

-36.6%

NASDAQ · Mkt cap $4.2 M

No news headlines were found in the last 48 hours, so the 36.6% decline cannot be attributed to a specific reported event. The drop likely reflects clinical trial results, regulatory setback, or delayed earnings announcement in a small-cap biotech stock.

Curis is a clinical-stage biopharmaceutical company focused on oncology and other disease areas, where stock movements are typically driven by trial data, FDA decisions, partnership announcements, or clinical updates. The absence of any news in the prior 48 hours does not rule out an intraday announcement—such stocks routinely gap on clinical or regulatory events. Alternatively, the decline could reflect a delayed market reaction to an announcement from the prior week, negative analyst commentary, or general weakness in small-cap biotech sentiment. Without access to the actual catalyst, we cannot distinguish between these possibilities, but for a company of this type, clinical or regulatory news is the most probable category of cause.

CAPS

Capstone Therapeutics CorpBasic Materials

$0.23−$0.10

-30.3%

NASDAQ · Mkt cap $2.9 M

Capstone Therapeutics reported strong Q2 results with revenue up 67% and gross profit up 92%, but the stock plunged 30% anyway, suggesting the market's sell-off reflects either unmet guidance expectations, concerns about sustainability, or a sharp repricing after a prior rally.

The news headlines are contradictory to the price action. Capstone announced materially positive Q2 2026 results with revenue growth of 67% and gross profit growth of 92%, and noted that the Stone Business Adjusted EBITDA turned positive as guided. These metrics would normally support a stock gain. However, the stock declined 30%, making it the ninth biggest loser of the day. This disconnect suggests either that forward guidance was disappointing relative to market expectations, that management commentary or a conference call revealed concerns about margin sustainability or competitive pressures, or that the market had previously overpriced the stock and used the earnings as an opportunity to correct. Without access to the full earnings release, guidance statements, or analyst commentary, the precise trigger remains unclear. The possibility of a capital raise, debt covenant concerns, or insider selling could also explain the move but would require additional information to confirm.

IPDN

Professional Diversity Network IncIndustrials

$0.28−$0.12

-30.1%

NASDAQ · Mkt cap $2.7 M

No news headlines are available in the last 48 hours to explain the 30% drop in IPDN. Without reporting, the cause remains unclear but could involve delayed earnings, insider trading activity, or broad market pressure on low-priced stocks.

The absence of any recent news headlines in the 48-hour window before this steep decline presents a clear evidentiary gap. A 30% single-day loss for a stock trading at $0.28 typically warrants some kind of public catalyst, yet none appears in the provided data. This could indicate several possibilities, none of which can be confirmed here: first, that significant news may have been released but failed to reach the Yahoo Finance RSS feed sampled, second that the decline reflects accumulating negative sentiment or a technical breakdown unconnected to discrete events, or third that insider activity or delayed disclosure triggered algorithmic selling. Professional Diversity Network Inc operates in the nonprofit/career services space, which can be vulnerable to funding changes, partnership withdrawals, or operational announcements that move the stock sharply. Without access to company filings, press releases, or broader financial news sources beyond the 48-hour window, attributing this move remains speculative.

GLND

Greenland Energy CompanyEnergy

$1.12−$0.48

-30.0%

NASDAQ · Mkt cap $62 M

Greenland Energy Company dropped 30% on news that its drilling partner Stampede Drilling has no rig currently available in Greenland, signaling project execution delays despite a permitting update from the JV partner.

On August 11, GLND released two pieces of news that appear contradictory in tone. The company announced a permitting update from its joint venture partner 80 Mile plc, which on its surface sounds constructive for project advancement. However, hours earlier, Stampede Drilling—the contracted drilling services provider—publicly confirmed it has no drilling rig deployed in Greenland and that the rig undergoing upgrades for potential Greenland deployment has not yet been mobilized. For an early-stage energy exploration company, this gap between permitting progress and actual operational readiness is material. The market appears to have interpreted the Stampede disclosure as evidence that project execution is substantially behind expectations, regardless of regulatory progress. Investors likely fear delays in exploration drilling will push back value-creation milestones and cash burn timelines.

BBLG

Bone Biologics CorpHealthcare

$0.65−$0.23

-26.3%

NASDAQ · Mkt cap $1.2 M

Bone Biologics announced positive news on rhNELL-1 shelf life extension on August 12, yet the stock dropped 26.27%, suggesting the market either already priced in this milestone, views it as insufficient relative to near-term clinical or commercial timelines, or sold on the news due to broader bi…

The news released on August 12 describes a technical achievement—extending validated shelf life from an unstated prior duration to 32 months—framed positively as enhancing manufacturing flexibility and supporting pivotal study readiness. However, the stock's severe single-day decline contradicts the ostensibly favorable nature of this announcement. This pattern is common in biotech when: (1) the market anticipated this milestone and had already incorporated it into the stock price, leading to a sell-the-news reaction; (2) investors interpret the announcement as confirmatory rather than transformative, lacking sufficient clinical or commercial catalyst; or (3) other negative developments not captured in these two brief headlines—such as insider selling, trial setback, financing dilution, or analyst downgrade—occurred simultaneously. The headlines themselves contain no adverse information, clinical data, or guidance changes that would directly explain the move.

GITS

Hanryu Holdings, Inc.Communication Services

$2.10−$0.72

-25.5%

NASDAQ · Mkt cap $6.2 M

No news headlines were available in the last 48 hours to explain GITS's 25.46% decline, so the cause remains unclear without additional information or market context.

The absence of recent news makes it impossible to pinpoint a specific catalyst for this sharp 25.46% drop. GITS appears to be a small-cap stock trading at $2.10, which makes it susceptible to several generic categories of moves: market-wide volatility or sector rotation, a delayed negative earnings report or guidance warning that hasn't yet surfaced in the news feed, insider selling or analyst downgrade not yet syndicated to major RSS feeds, technical breakdown through key support levels, or liquidity-driven selling in lower-volume securities. Without either recent news or known structural characteristics of the company or security, it is not possible to distinguish among these hypotheses. A direct check of company filings, press releases, or broker research would be necessary to determine the actual driver.

DAIC

CID HoldCo, Inc.Technology

$0.55−$0.19

-25.4%

NASDAQ · Mkt cap $508 K

No news headlines were found in the last 48 hours, so the 25% drop cannot be directly attributed to a published announcement; the cause likely involves delayed news disclosure, technical selling, or a market event not yet covered by the feeds reviewed.

The absence of any news in the Yahoo Finance RSS for the prior 48 hours makes it difficult to pinpoint a specific catalyst for DAIC's sharp 25% decline. CID HoldCo is a small-cap stock, and such securities are often sensitive to liquidity events, insider transactions, earnings misses, or regulatory developments that may not immediately appear in major news aggregators. Possible categories of cause include delayed earnings or guidance revision, short-seller activity or a related disclosure, a dilutive financing announcement, or technical breakdown in a thinly traded security. Without access to company filings, press releases, or real-time trading data, attribution remains speculative.

OSRH

Bellevue Life Sciences Acquisition Corp.Healthcare

$0.29−$0.10

-25.1%

NASDAQ · Mkt cap $21 M

OSRH fell 25% despite a CEO statement reaffirming confidence and highlighting subsidiary business development on August 11, suggesting the market either discounted the positive messaging or reacted to an unstated adverse catalyst not reflected in the headline provided.

The only headline available is a CEO affirmation of confidence and subsidiary business development progress, which is typically neutral to mildly positive messaging. However, the stock declined sharply the following day, ranking 15th among daily losers. This disconnect suggests either the full press release contained material headwinds not captured in the headline snippet, market participants viewed the statement as insufficient to address underlying concerns, or an entirely separate negative catalyst drove the move. SPAC-related securities like this one are sensitive to delistings, compliance failures, merger deal deterioration, or redemptions. Without additional reporting, the specific trigger remains unclear, though the timing suggests investors may have reacted negatively to something announced or discovered on August 11.

GSUN

Golden Sun Education Group LimitedConsumer Defensive

$0.35−$0.11

-23.5%

NASDAQ · Mkt cap $3.5 M

Golden Sun Education Group dropped 23.5% on no identifiable news in the last 48 hours, suggesting either a delayed announcement, technical selloff, or sector-wide pressure in China-listed education stocks not captured in the provided headlines.

No news headlines were available in the last 48 hours to explain this sharp 23.5% decline. Golden Sun Education is a China-focused education company trading over the counter on NASDAQ, a profile that can be sensitive to several unstated catalysts: regulatory announcements affecting Chinese education platforms, foreign exchange pressure on the yuan, broad delisting concerns affecting Chinese equities, insider trading activity, or shifts in institutional ownership. Without fresh news coverage, the move appears disconnected from publicized company-specific events. The magnitude of the drop (ranking 16th biggest loser of the day) suggests either material negative information that has not yet surfaced in major RSS feeds, or technical factors such as low liquidity amplifying a smaller initial seller. Education stocks in particular have faced structural headwinds from Chinese regulation in recent years, which could explain sector-wide pressure even absent fresh headlines.

JWEL

Jowell Global Ltd.Consumer Cyclical

$3.00−$0.91

-23.3%

NASDAQ · Mkt cap $5.8 M

JWEL dropped 23.27% with no news reported in the last 48 hours, suggesting the move was driven by either a delayed announcement, technical selling, or market rumors not yet reflected in mainstream headlines.

No recent news headlines are available to explain JWEL's sharp 23 percent single-day decline. This lack of reported catalyst creates genuine uncertainty about the cause. A move of this magnitude typically correlates with material corporate events such as earnings misses, guidance cuts, executive departures, regulatory setbacks, or significant contract losses. Without headline confirmation, the decline could reflect delayed disclosure of bad news, short squeeze unwinding, technical breakdown through a support level, or unconfirmed market chatter. For a company trading at $3.00, liquidity or delisting risk could also trigger sharp selloffs if investors become concerned about exchange compliance. Without access to intraday trading patterns, insider transactions, or pre-market announcements, it is not possible to pinpoint the mechanism.

FAMI

Farmmi IncConsumer Defensive

$0.13−$0.04

-21.9%

NASDAQ · Mkt cap $3.9 M

Farmmi received a NASDAQ notification on August 11 that it is not in compliance with minimum bid price requirements, triggering a 21.9% sell-off as investors react to potential delisting risk.

The headline explicitly states that Farmmi received a letter from NASDAQ on August 11, 2026 notifying the company of non-compliance with minimum bid requirements. While the RSS snippet is truncated and does not provide the full details (such as the specific bid price threshold, cure period, or remediation options), NASDAQ compliance violations—particularly those related to minimum bid prices—are material events that directly threaten a company's exchange listing status. Shareholders typically respond with immediate and sharp selling when delisting risk emerges, as it reduces liquidity, institutional eligibility, and perceived legitimacy. The 21.9% single-day decline is consistent with the severity of a listing compliance notice. No offsetting positive news is present to buffer the decline.

SNYR

Synergy CHC Corp.Healthcare

$0.13−$0.03

-20.8%

NASDAQ · Mkt cap $1.6 M

No news headlines were found in the last 48 hours, so the 20.81% drop cannot be attributed to a specific announced event. The decline likely reflects either technical selling pressure, delayed news reaction, or a sector-wide move.

With zero news items available in the last two days, no specific catalyst can be identified from the provided information. SNYR is a micro-cap stock trading at $0.13, which makes it highly susceptible to liquidity-driven moves, short-covering reversals, and sentiment shifts that may not require headline catalysts. Possible explanations for this tier of stock include profit-taking after a prior run, broad sector weakness in healthcare or specialty services, deterioration in fundamentals that may not yet have reached mainstream news wires, or simple lack of buying interest. Without access to earnings releases, clinical trial results, financing announcements, or insider transactions that may not yet be indexed by Yahoo Finance, attributing the move to a specific cause would be speculation.

WXM

WF International Limited Ordinary SharesIndustrials

$4.74−$1.19

-20.7%

NASDAQ · Mkt cap $13 M

WXM fell 20.72% on August 12, 2026, but no news headlines were published in the prior 48 hours, so the direct catalyst remains unknown. The drop may reflect delayed market reaction to an earlier announcement, technical selling, or market-wide sector pressure.

No headlines from Yahoo Finance RSS appear in the last 48 hours to explain WXM's sharp 20.72% decline. This disconnect between a material single-day loss and the absence of contemporaneous news suggests either that the relevant catalyst was published earlier and the market is repricing it with a lag, or that the move stems from factors not captured in headline feeds such as technical breakdown, options expiration activity, broader sector rotation out of international or consumer retail plays, or undisclosed rumors in market channels. WXM is an ordinary share offering from WF International Limited, a holding that may be exposed to foreign exchange headwinds or regional economic data shifts that spark repricing without formal corporate announcements. Without access to intraday order flow, pre-market moves, or statements from the company itself, attribution remains speculative.

MAAS

Highest Performances Holdings Inc. - American Depository SharesFinancial Services

$16.37−$4.32

-20.7%

NASDAQ · Mkt cap $7.0 B

MAAS fell 20.68% despite announcing completion of a RMB1.65 million AI computing contract with full payment received, suggesting the market either viewed the deal size as insufficient, has concerns unrelated to this news, or the stock was already overextended before the announcement.

The most recent headline reports a positive operational milestone: the company's subsidiary completed delivery of five AI computing nodes to a client, received full payment for the RMB1.65 million contract, and is providing ongoing technical support. Ordinarily, completion of a contract with full payment collection would be viewed constructively. However, the stock declined sharply the same day. This disconnect could reflect several possibilities. First, the contract value may be smaller than investor expectations for a company in the high-performance AI infrastructure space. Second, the market may have been pricing in a larger announcement and interpreted this as disappointing guidance or forward outlook. Third, the decline may reflect broader sector weakness, profit-taking after a prior rally, or undisclosed negative developments not captured in the available headlines. Without access to the full press release details, guidance commentary, or trading context from the previous session, attribution remains uncertain.

GLE

Global Engine Group Holding Limited Ordinary SharesTechnology

$0.39−$0.10

-20.5%

NASDAQ · Mkt cap $6.8 M

GLE dropped 20% despite announcing a strategic collaboration with Angkasa-X on August 11, suggesting the market viewed the deal announcement as underwhelming, dilutive, or less material than anticipated.

Global Engine Group released two nearly identical announcements on August 11 regarding an advancement of its space-to-AI infrastructure partnership with Angkasa-X, progressing from a May memorandum of understanding to a proof-of-concept in Sarawak. The timing suggests this news broke the day before the stock's 20% decline. Possible explanations include: market disappointment that the deal remained a proof-of-concept rather than a larger commercial commitment, concern about dilution from equity issuance to finance the collaboration, skepticism about the company's ability to execute on ambitious AI and satellite infrastructure claims, or technical selling following the announcement. Without details on deal terms, financial commitments, or revenue expectations, the exact driver of negative sentiment is unclear, though the magnitude of the drop suggests structural concern rather than routine volatility for a sub-$0.40 microcap.

BKHAR

Black Hawk Acquisition Corporation Rights

$1.31−$0.33

-20.1%

NASDAQ · Mkt cap $1.7 M

No news headlines were reported in the last 48 hours, so the cause of the 20.12% decline is unclear; the move may reflect technical selling, SPAC redemption activity, or a delayed market reaction to an earlier announcement.

Black Hawk Acquisition Corporation Rights (BKHAR) dropped significantly with no corresponding news in the Yahoo Finance feed over the past two days. Rights offerings in SPACs are inherently volatile instruments, particularly as they approach expiration or exercise deadlines. The security could be declining due to several structural factors: (1) erosion in the underlying SPAC's value, which directly pressures rights; (2) technical selling near historical resistance or psychological levels; (3) a gap between the rights exercise price and current market conditions making exercise economically disadvantageous; or (4) a market event or announcement that occurred more than 48 hours ago but is only now showing delayed price impact. Without contemporaneous headlines, we cannot establish a specific catalyst.

EONR.WT

EON Resources Inc WT

$0.08−$0.02

-19.9%

AIEV

Thunder Power Holdings, Inc.Consumer Cyclical

$0.14−$0.03

-19.6%

NASDAQ · Mkt cap $21 M

No news headlines were reported in the last 48 hours, so the 19.58% drop cannot be attributed to a specific disclosed event. The decline is likely driven by general market sentiment, technical selling, or undisclosed developments.

Thunder Power Holdings is a micro-cap stock trading at $0.14, and the absence of recent news makes it difficult to pinpoint a definitive cause for the sharp 19.58% single-day decline. Stocks in this price range and market-cap tier are often subject to high volatility, thin liquidity, and sensitivity to institutional selling or margin pressures. Possible contributors could include sector-wide weakness in electric vehicle or battery stocks, forced liquidations, or technical breakdown through support levels. Without headlines or public filings, the exact trigger remains unknown. Investors should check SEC filings, company investor relations channels, or social media for any announcements that may not yet be reflected in mainstream news feeds.

BBBY.WT

Bed Bath & Beyond, Inc. WT

$0.32−$0.08

-19.3%

OBX

Obsidian Therapeutics, Inc.Healthcare

$28.00−$6.26

-19.1%

TGE.WT

The Generation Essentials Group

$0.15−$0.03

-19.1%

NYSE

No news headlines were found in the last 48 hours, so the 19% drop likely reflects either a broader market sell-off, technical weakness in a low-priced speculative name, or an unreported catalyst that has not yet surfaced in major financial media.

The absence of any recent news in the Yahoo Finance RSS feed means we cannot point to a specific company announcement, earnings release, regulatory action, or market event tied to this stock. TGE.WT is a warrant (note the .WT ticker suffix), which means it is a leverage instrument tied to an underlying equity and typically exhibits higher volatility. Warrants can decline sharply on reduced trading interest, widening bid-ask spreads, decay in implied volatility, or moves in the underlying stock. A 19% single-day loss in a warrant could reflect either a decline in the underlying equity itself, reduced investor appetite for leveraged exposure, or simply illiquidity in a low-price security. Without headlines or structural data, the move remains unexplained by publicly reported information.

NTHI

NEONC TECHNOLOGIES HOLDINGS, INC.Healthcare

$3.43−$0.81

-18.6%

NASDAQ · Mkt cap $120 M

NeOnc reported strongly positive Phase 2a data on August 12 that beat historical benchmarks by 2.5x, yet the stock fell 18.64% the same day, suggesting a sell-the-news reaction or that market expectations had already priced in an even more optimistic outcome.

The headline evidence presents a paradox. NeOnc announced Phase 2a results for NEO100 showing 48.9% six-month progression-free survival versus a 20% historical benchmark, with median overall survival near 26 months. The company plans to request an FDA Type B meeting for a registrational pathway in an unmet-need indication. One headline from August 12 at 13:39 UTC states shares "climbed 11%," yet the closing price reflects an 18.64% loss. This suggests the stock may have initially rallied on the news but reversed sharply intraday or at close. Possible explanations include: (1) investors had previously anticipated even stronger data and are disappointed despite the objective beat, (2) dilution concerns or secondary offering timing coincided with the release, (3) sell-the-news momentum by early buyers, or (4) a separate negative catalyst emerged after the positive headline. The data itself is objectively strong, but biotech stocks often face volatility around clinical milestones regardless of outcome quality.

DRMA

Dermata Therapeutics, Inc. Common StockHealthcare

$1.37−$0.29

-18.0%

NASDAQ · Mkt cap $5.8 M

Dermata's Q2 2026 earnings and corporate update announced on August 11th likely disappointed investors despite confirming the August 25 launch of its first commercial product Tome, triggering an 18% single-day sell-off in this pre-revenue biotech stock.

The headline confirms Dermata announced Q2 2026 financial results and provided a corporate update on August 11, with the key detail being confirmation of an August 25 launch date for Tome Foundational Treatment. However, the headline does not disclose the actual financial results, cash position, guidance, or any operational metrics that would explain the sharp 18% decline. For early-stage biotech and dermatology companies approaching commercial launch, investors often sell on concerns about cash runway, burn rate, manufacturing readiness, competitive positioning, or unmet guidance expectations. The timing of the launch announcement alone would typically be positive news, so the decline suggests the earnings results or guidance contained concerning details not summarized in the headline snippet provided here. Without access to the full earnings release or analyst commentary, the specific disappointment cannot be pinpointed.

INTZ

Intrusion, Inc.Technology

$0.67−$0.15

-18.0%

NASDAQ · Mkt cap $14 M

Intrusion Inc. reported Q2 2026 earnings on August 11 with a 30% earnings miss and 3.13% revenue miss versus estimates, triggering an 18% stock decline the following trading day.

The earnings report released after market close on August 11 is the direct catalyst for the 17.98% drop on August 12. The company delivered a negative earnings surprise of 30% while also missing revenue expectations by 3.13%. Although the press release mentions sequential revenue growth and the VigilAigent acquisition as positive drivers for future profitability visibility, the immediate market reaction reflects disappointment in current-quarter performance relative to consensus expectations. For a micro-cap company trading near $0.67, earnings misses of this magnitude typically trigger sharp sell-offs as they erode investor confidence in management guidance and near-term execution. The magnitude of the earnings miss (30%) versus the revenue miss (3.13%) suggests the profitability challenge was more severe than top-line weakness alone would indicate.

CBRG

Chain Bridge IFinancial Services

$6.74−$0.96

-17.5%

AMIX

Autonomix Medical, Inc. Common StockHealthcare

$7.54−$1.58

-17.3%

NASDAQ · Mkt cap $5.7 M

Autonomix Medical announced completion of a positive GLP preclinical study supporting FDA submission, yet the stock fell 17.32%, suggesting the market either expected a more substantial milestone or reacted to unrelated negative sentiment or broader selloff pressure.

The headline announces a concrete achievement—completion of a GLP preclinical study with results supporting both safety and performance objectives, positioned as a key step toward FDA submission. This is typically viewed as a favorable development for a clinical-stage biotech company. However, the stock experienced a significant intraday decline, ranking as the 33rd biggest loser on the day. This disconnect suggests several possibilities. First, investors may have anticipated a more advanced milestone (such as IND approval or Phase 1 initiation) rather than preclinical completion, making the announcement disappoint relative to expectations. Second, the stock could be experiencing profit-taking after a prior rally, or it may have been caught in a broader market selloff unrelated to company-specific fundamentals. Third, sell-side analyst downgrades or revised guidance issued simultaneously with the announcement cannot be ruled out based on the information provided. Without access to the full press release details, analyst responses, or broader market context on that date, the precise mechanism remains ambiguous.

IPCX

Inflection Point Acquisition Corp. IIIFinancial Services

$4.50−$0.92

-17.0%

NASDAQ · Mkt cap $136 M

No news headlines were found in the last 48 hours for IPCX, so the 16.97% drop likely stems from broader market conditions, trader activity on the blank-check company, or delayed news not yet indexed by the feed.

IPCX is an acquisition company (SPAC), which means its price typically depends on investor sentiment toward its merger target, deal timing, regulatory approvals, or the overall SPAC market environment rather than operational earnings. Without headlines in the past 48 hours, the sharp drop cannot be directly linked to company-specific news. Possible drivers include: (1) technical or momentum selling if the stock had rallied recently and hit resistance, (2) sector-wide weakness in SPACs or blank-check companies due to regulatory scrutiny or market rotation, or (3) delayed disclosure of merger delays, shareholder votes, or regulatory feedback that may not yet appear in the news feed. The lack of news does not rule out a material event; it may simply mean the information has not yet been widely reported or indexed.

AREN

The Arena Group Holdings, Inc.Communication Services

$1.31−$0.27

-17.0%

NYSE · Mkt cap $50 M

Arena Group reported Q2 2026 earnings with significant revenue and EBITDA declines, and despite announcing a strategic pivot to AI with a rebrand to Paradium.AI and acquisitions, investors reacted negatively to the deteriorating fundamentals.

The Arena Group released Q2 2026 results on August 10 showing material drops in both revenue and adjusted EBITDA. While management simultaneously announced an aggressive repositioning as an AI technology firm, including a corporate rebrand to Paradium.AI, completion of the InfoSentience acquisition, debt refinancing, and launch of Cutter Studios, the market appears to have focused on the negative earnings results rather than the forward-looking strategic narrative. The -16.96% one-day drop suggests investors are skeptical about the turnaround thesis or concerned that current operational performance does not justify the transformation story, particularly given the steep declines in core financial metrics reported in the same announcement.

FRVO

Fervo Energy CompanyUtilities

$20.20−$4.10

-16.9%

NASDAQ · Mkt cap $5.1 B

Fervo Energy fell 16.87% on Q2 earnings day, likely driven by investor disappointment with financial results or forward guidance despite operational progress announcements on capacity expansion and land position growth.

Fervo reported Q2 2026 results and held an earnings call on August 12, 2026. The headlines confirm operational achievements: 400 megawatts advanced into development in Q2 and over 650,000 acres of mineral rights secured. However, the stock fell sharply on the same day these results were announced, which typically signals that investors found the financial performance, profitability trajectory, cash burn rate, or forward guidance disappointing relative to expectations. The operational metrics appear positive in isolation, but earnings-day selling of this magnitude usually reflects either missed earnings expectations, reduced guidance, higher capital requirements, or other financial metrics that spooked the market. The news summaries provided do not include specific financial figures, margins, losses, revenue numbers, or guidance statements that would explain the disconnect between operational progress and the stock decline, leaving the precise financial disappointment unspecified but the timing and magnitude of the drop consistent with earnings miss reactions.

SECZ

Securitize Corp.Technology

$7.95−$1.23

-16.7%

NYSE · Mkt cap $1.2 B

A single headline from two days ago notes that SECZ stock has fallen 31.5% year-to-date and remains expensive by valuation metrics despite the decline; the 16.66% drop today likely reflects continued selling pressure amid weak sentiment and lack of positive catalysts.

The only news item provided is from August 10th, which is prior to the August 12th drop, and does not report a specific new catalyst but rather observes that the stock has already fallen sharply year-to-date while maintaining a rich valuation. This backward-looking observation does not directly explain today's intraday move. However, the headline does establish that negative sentiment around SECZ's valuation and performance is in the market; the 16.66% single-day drop could reflect either a delayed market reaction to valuation concerns, a new piece of information not captured in the RSS feed provided, or technical selling in a stock already under pressure. Without additional news or earnings releases in the last 48 hours, the specific trigger for today's move is unknown. Securitize operates in the digital securities space, which can be sensitive to regulatory developments and market sentiment shifts that may not always appear in mainstream financial headlines.

LAX

8i Acquisition 2 Corp. Ordinary Shares

$13.30−$2.60

-16.4%

WFF

WF Holding Limited Ordinary SharesIndustrials

$1.63−$0.31

-16.1%

NASDAQ · Mkt cap $20 M

WFF dropped 16.07% on August 12, 2026, with no news headlines found in the last 48 hours, suggesting either a delayed market reaction to an earlier announcement, technical selling, or an undisclosed development not yet reflected in major financial news feeds.

The absence of recent headlines makes it difficult to pinpoint a specific catalyst for the 16% decline. WF Holding Limited is a smaller-cap security, and such stocks are often subject to heightened volatility from technical factors, sector rotation, or news that circulates through less-monitored channels before reaching mainstream financial media. Possible explanations include a delayed market reaction to an earnings release or guidance revision issued outside the 48-hour window, insider selling or offering announcements, deterioration in the underlying business or sector conditions, or liquidity-driven selling in a thin trading environment. Without access to intra-day commentary, regulatory filings, or company communications from the relevant date, we cannot confirm which category applies.

APVO

Aptevo Therapeutics IncHealthcare

$3.50−$0.64

-15.4%

NASDAQ · Mkt cap $4.1 M

Aptevo announced a $4.5 million warrant exercise and PIPE financing on the same day the stock fell 15.38%, suggesting market concern about dilution despite the capital raise.

Aptevo disclosed the exercise of existing warrants and a PIPE investment totaling $4.5 million gross proceeds on August 12, 2026. For a clinical-stage biotech company, warrant exercises and PIPE offerings are dilutive events that increase share count without immediate revenue generation. While the capital infusion itself may be necessary for funding ongoing development of the company's multispecific immuno-oncology therapeutics, markets often penalize the announcement of such financings, particularly if the implied valuation or terms are viewed as unfavorable or if the amount raised appears modest relative to burn rate. The 15.38% decline on the day of announcement is consistent with dilution-driven selling, though without details on the warrant exercise price, PIPE terms, or pre-announcement technical conditions, we cannot rule out concurrent negative sentiment or broader biotech sector weakness as contributing factors.

SILO

Silo Pharma Inc.Healthcare

$3.03−$0.55

-15.4%

NASDAQ · Mkt cap $4.5 M

No news headlines were found in the last 48 hours, so the cause of SILO's 15.36% drop cannot be directly attributed to a specific announced event. The decline likely reflects sector-wide pressure, technical selling, or an undisclosed development not yet captured by major news feeds.

With zero headlines available for the past two days, we cannot point to a concrete catalyst such as clinical trial results, FDA action, earnings miss, or financing news. For small-cap biotech and pharma stocks like Silo, sharp single-day declines commonly stem from several sources including negative clinical data, secondary offering announcements, insider selling, analyst downgrades, or sector-wide risk-off moves in small-cap equities. The stock's rank as the 41st biggest loser suggests this is a market-wide correction day rather than isolated idiosyncratic weakness, though without news confirmation this remains inference. The absence of any news in a 48-hour window around a 15% drop is itself notable and could indicate the news simply has not yet propagated to major feeds, or the move is technical rather than fundamental.

INDP

Indaptus Therapeutics, Inc.Healthcare

$1.02−$0.18

-15.0%

NASDAQ · Mkt cap $125 M

No news headlines appeared in the last 48 hours for INDP, so the 15% intraday drop lacks a publicly documented catalyst. This kind of move in a small-cap biotech stock typically reflects sector rotation, technical selling, or unreported developments.

The absence of any Yahoo Finance headlines in the 48 hours preceding the drop makes it impossible to tie the move to a specific corporate announcement, regulatory decision, or market event. INDP is a small-cap biotech company, a category that experiences high volatility and is sensitive to shifts in investor sentiment toward early-stage therapeutics, funding conditions, and clinical trial outcomes. A 15% single-day loss in this space could stem from a broad sector selloff, a delayed clinical announcement that did not reach major news feeds, insider trading activity, short-covering reversal, or simply technical support breaking on low volume. Without confirmed headlines, attributing causation to any specific event would be speculation.

ROLR

High Roller Technologies, Inc.Consumer Cyclical

$5.71−$1.00

-14.9%

NYSE · Mkt cap $60 M

High Roller Technologies reported lower Q2 revenue and wider operating losses while reducing legacy casino operations, triggering a 14.90% sell-off as investors reacted to deteriorating financial performance and strategic restructuring headwinds.

The earnings call headline explicitly states that ROLR delivered lower second-quarter revenue combined with a wider operating loss. The company is simultaneously reducing certain legacy online casino activities while investing in a planned U.S. launch, suggesting a transition period with near-term margin pressure and execution risk. This combination of missed topline expectations, deteriorating profitability, and capital allocation toward an unproven new initiative typically triggers sharp selloffs in growth-sensitive or cyclical gaming stocks. The 43rd biggest loser ranking and 14.90% decline are consistent with a material earnings miss or significantly lowered guidance. Without the full earnings release details, we cannot determine whether the stock also withdrew guidance or missed consensus estimates, but the headline language strongly implies an underperformance event that justified the market's sharp repricing downward.

INUV

Inuvo IncTechnology

$0.86−$0.15

-14.8%

PONOR

Pono Capital Four, Inc. Rights

$0.23−$0.04

-14.8%

NASDAQ

No news headlines appeared in the last 48 hours, so the 14.78% decline cannot be attributed to a specific disclosed event. PONOR rights are likely sensitive to broader market conditions or SPAC-related developments.

PONOR is a rights offering associated with a SPAC (Pono Capital Four), a security class that typically trades on sentiment around the underlying merger/acquisition prospects, redemption risk, and warrant/share arbitrage dynamics rather than on direct company fundamentals. The absence of any news in the last 48 hours suggests the decline was not driven by a major announced catalyst. Rights offerings are inherently illiquid and volatile instruments; price moves often reflect shifts in the probability or valuation of the target business, changes in investor demand for SPAC exposures, or technical/redemption-related selling. Without headlines, the drop could stem from a negative development announced more than 48 hours ago still reverberating, a shift in overall SPAC sentiment, or routine thinly-traded volatility.

STRO

Sutro Biopharma IncHealthcare

$21.33−$3.68

-14.7%

NASDAQ · Mkt cap $363 M

Sutro Biopharma disclosed early STRO-004 Phase 1 data on August 12 showing partial responses but limited efficacy details, prompting a 14.71% selloff that H.C. Wainwright characterizes as an overreaction to underwhelming clinical efficacy.

The company reported Q2 2026 results and provided an early update on its STRO-004 Phase 1 study on August 12, highlighting confirmed and ongoing partial responses with favorable tolerability and pharmacokinetics. However, the market's sharp 15% decline suggests investors found the efficacy disclosure insufficient or disappointing relative to expectations. H.C. Wainwright's same-day commentary frames the selloff as an overreaction to the limited efficacy details rather than fundamentally bad data, implying the market may have anticipated stronger clinical signals. For a clinical-stage biotech stock, Phase 1 efficacy readouts are high-stakes catalysts that drive valuation swings based on how the data compares to prior hype or investor hopes. The timing of the decline on the announcement day, combined with analyst commentary questioning the market's reaction, indicates the stock move is directly tied to how the STRO-004 update was received.

TWLVR

Twelve Seas Investment Company III Rights

$0.15−$0.02

-14.5%

NASDAQ

No news headlines are available in the last 48 hours, so the 14.51% drop cannot be attributed to a specific announced catalyst. Rights offerings typically decline when the underlying warrant or redemption terms become less valuable.

The absence of recent news headlines means we cannot point to a concrete event such as earnings, regulatory action, or corporate announcement. However, Twelve Seas Investment Company III Rights is a blank-check company rights offering, a security class particularly sensitive to shifts in SPAC sentiment, redemption economics, and the market's appetite for de-SPAC transactions. Rights decline in value when the underlying economics deteriorate—for instance, if the sponsor's deal prospects weaken, redemption assumptions change, or broader SPAC market sentiment cools. The 14.51% single-day loss sits at the extreme end but is not unusual for micro-cap rights, which exhibit high volatility even on light trading days. Without news, the move likely reflects either technical pressure in a thin-liquidity security, delayed market reaction to an earlier announcement, or a shift in investor appetite for blank-check vehicles.

DYAI

Dyadic International IncHealthcare

$0.89−$0.15

-14.4%

NASDAQ · Mkt cap $30 M

Dyadic announced Q2 2026 earnings today claiming accelerating commercialization momentum, but the stock fell 14.42%, suggesting the market's interpretation of results or guidance disappointed despite the positive headline framing.

Dyadic released second quarter 2026 financial results on August 12, 2026, with a press release headline emphasizing accelerating commercialization momentum across key business areas. However, the stock dropped sharply the same day, ranking as the 48th biggest loser on NASDAQ. The disconnect between the upbeat headline and the price decline is notable. This pattern typically occurs when headline claims of momentum mask weaker-than-expected financials, disappointing guidance, margin compression, cash burn concerns, or reduced partnership visibility. For a small biotech or applied biotech company like Dyadic, investors often focus on cash runway, revenue growth rates, and near-term milestone achievement rather than qualitative claims. The earnings call scheduled for 5:00 pm ET on August 12 may provide additional clarity, but the pre-call selling suggests the market either previewed unfavorable details in the press release or had negative expectations that were not met by the actual numbers.

IZEA

IZEA Worldwide IncCommunication Services

$3.06−$0.51

-14.3%

NASDAQ · Mkt cap $53 M

IZEA plunged 14.29% following Q2 2026 earnings that revealed a 36% revenue decline to $5.8 million, despite management highlighting enterprise transition progress and a strong M&A pipeline.

The stock's sharp decline appears driven by the stark revenue contraction disclosed in Q2 results, which dominated the headlines across all three news items. While management framed the quarter positively by emphasizing record client engagement, a robust M&A pipeline, and progress on an enterprise-focused growth strategy, the 36% year-over-year revenue drop is a significant headwind that the market is pricing negatively. The company attributed delays to macroeconomic uncertainty affecting enterprise customer marketing decisions, a structural headwind beyond management's control. Investors may be interpreting the revenue collapse as a sign that the strategic pivot away from small- and midsize-business customers toward enterprise is not yet delivering offsetting revenue gains. Forward guidance or commentary on when the pivot would stabilize margins and resume growth would be critical context we lack from the headlines provided.

LIQT

LiqTech International IncIndustrials

$0.61−$0.10

-14.2%

NASDAQ · Mkt cap $18 M

LiqTech reported Q2 2026 earnings today with revenue missing estimates by 27%, likely triggering the 14% sell-off despite a modest earnings beat and a new steel manufacturer contract announcement.

On August 12, LiqTech announced second quarter 2026 financial results alongside an earnings call summary. The key headwind is a significant revenue miss: the company delivered revenue 27.27% below consensus estimates for the quarter ended June 2026, despite beating earnings expectations by 26.32%. While the earnings surprise is positive, suggesting margin control or reduced losses, the revenue shortfall is a material disappointment for investors evaluating a clean technology company whose value depends on top-line growth and market adoption. The company did announce a follow-on order from a US-based steel manufacturer on August 11, which is positive, but this win appears insufficient to offset investor concerns about revenue trajectory and market demand. The 14% single-day drop ranks LIQT as the 50th biggest loser on NASDAQ, suggesting broad-based sell pressure tied directly to the earnings release.